Information Provided By:
Fly News Breaks for May 3, 2019
CBM
May 3, 2019 | 08:31 EDT
As previously reported, Baird analyst Evan Stover downgraded Cambrex to Neutral from Outperform, stating that while he still believes in "the end-to-end small molecule story," he thinks much of the near-term multiple expansion opportunity is reflected in the stock as shares have rallied about 20% from their February lows. Also, the 2019 M&A ramp from integrating Halo and Avista is "a little steeper" than he expected, added Stover, who keeps a $44 price target on Cambrex shares.
News For CBM From the Last 2 Days
There are no results for your query CBM